 Medicare Part D
"Medicare Part D" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stand-alone drug plan offered by insurers and other private companies to beneficiaries that receive their Medicare Part A and/or B benefits through the Original Medicare Plan. It includes Medicare Private Fee-for-Service Plans that do not offer prescription drug coverage and Medicare Cost Plans offering Medicare prescription drug coverage. The plan was enacted as the Medicare Prescription Drug, Improvement and Modernization Act of 2003 with coverage beginning January 1, 2006.
| Descriptor ID |
D054524
|
| MeSH Number(s) |
N03.219.521.576.343.575.500 N03.219.521.576.343.840.938 N03.706.615.752
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Medicare Part D".
Below are MeSH descriptors whose meaning is more specific than "Medicare Part D".
This graph shows the total number of publications written about "Medicare Part D" by people in this website by year, and whether "Medicare Part D" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 1 | 2 | | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Medicare Part D" by people in Profiles.
-
Nguyen AM, Anderson KE, Anderson G, Johnson TV. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US. JAMA Ophthalmol. 2022 09 01; 140(9):855-862.
-
Anderson KE, Alexander GC, Ma C, Dy SM, Sen AP. Medicare Advantage coverage restrictions for the costliest physician-administered drugs. Am J Manag Care. 2022 07 01; 28(7):e255-e262.
-
Hussaini SMQ, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, Alexander GC. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Netw Open. 2022 03 01; 5(3):e221117.
-
Goel V, Moran B, Kaizer AM, Sivanesan E, Patwardhan AM, Ibrahim M, DeWeerth JC, Shannon C, Shankar H. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study. Anesth Analg. 2021 06 01; 132(6):1748-1755.
-
de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021 04 20; 96(16):e2132-e2137.
-
Abraham R, Wilkinson E, Jabbarpour Y, Petterson S, Bazemore A. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients. J Am Board Fam Med. 2020 Jan-Feb; 33(1):9-16.
-
Lind KE, Hildreth K, Lindrooth R, Morrato E, Crane LA, Perraillon MC. Effect of Medicare Part D on Ethnoracial Disparities in Antidementia Medication Use. J Am Geriatr Soc. 2018 09; 66(9):1760-1767.
-
Chang LL, Xu H, DeVore AD, Matsouaka RA, Yancy CW, Fonarow GC, Allen LA, Hernandez AF. Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure. J Am Heart Assoc. 2018 04 01; 7(7).
-
Gastala NM, Wingrove P, Gaglioti A, Petterson S, Bazemore A. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs. Health Aff (Millwood). 2016 07 01; 35(7):1237-40.
-
Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis. J Manag Care Spec Pharm. 2015 Oct; 21(10):956-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|